Efficacy of Methylprednisolone with Dexamethasone in patients with Severe Covid Pneumonia in Term of Clinical and Biochemical Improvement

被引：3

作者：

Aslam, Javaria ^{[1
]}

Masroor, Momina ^{[2
]}

Ahmad, Sami ^{[3
]}

Hussain, Wajahat ^{[4
]}

Mansoor, Hurria ^{[2
]}

Khan, Laraib ^{[2
]}

机构：

[1] Quaid e Azam Med Coll, Med, Bahawalpur, Pakistan

[2] Sir Sadiq Abbasi Hosp, Dept Med, WMO, Bahawalpur, Pakistan

[3] Quaid e Azam Med Coll BVH, Pulmonol, Bahawalpur, Pakistan

[4] Quaid e Azam Med Coll, Dept Community Med, Bahawalpur, Pakistan

来源：

PAKISTAN JOURNAL OF MEDICAL & HEALTH SCIENCES | 2021年 / 15卷 / 10期

关键词：

Methylprednisolone; Dexamethasone; COVID pneumonia;

D O I：

10.53350/pjmhs2115102635

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Aim: Efficacy of Methylprednisolone with Dexamethasone in patients with severe COVID pneumonia in term of clinical and biochemical improvement. Methodology: Cross Sectional analytical study conducted among COVID-19 patients admitted in HDU of Sir Sadiq Hospital, Bahawalpur from May, 2021 to June 2021 after taking approval from institutional ethical committee. 82 patients were included in this study after taking informed consent. Patients were divided into two groups A and B i.e. I/V methyl prednisolone and I/V dexamethasone respectively. Each group was containing 41 patients. Primary outcome was measured in terms of decrease or increase in oxygen demand leading to discharge or shifting to Intensive Care Unit. CRP levels were also measured to assess biochemical improvement. Results: 31 (75.6%) patients from group A and 22(53.7%) from group B were improved and discharged and difference was statistically significant (p<0.05). Number of patients shifted to ICU were 10(24.4%) and 19(46.3%) from A and B groups respectively. Conclusion: In terms of clinical and biochemical response methylprednisolone outperforms dexamethasone.

引用

页码：2635 / 2636

页数：2

共 11 条

[1]

[Anonymous], 2021, WHO COVID 19 GLOBAL, P2021

[2] Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: results from a randomised controlled clinical trial [J].